ESLA stock news · Estrella Immunopharma, Inc.
Get alerts for ESLA
Follow Estrella Immunopharma, Inc. (ESLA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ESLAEstrella Immunopharma, Inc. has new leaders, including Cynthia Pussinen as CEO and Cheng Liu as Chief Scientific Officer.
NeutralEstrella named Cynthia Pussinen CEO and board chair, while Cheng Liu became chief scientific officer and stayed president. Her experience is relevant, but the filing leaves the company's prospects unchanged.
12 health care companies are seeing big changes in their stock prices today.
NeutralEstrella Immunopharma’s share price rose about 27% during Friday’s session, but the article gives no business reason for the move. It adds no new information about the company’s outlook.
12 health care companies are seeing big changes in their stock prices today.
NeutralThe article reports a fall in Estrella Immunopharma shares but gives no company news explaining it. The share move alone does not change what the article says about the company.
12 health care stocks are changing a lot before the market opens on Monday.
NeutralEstrella Immunopharma shares fell about 8% before trading began. The story gives no reason or company news, so it does not change the company's business outlook.
12 health care companies are changing prices before the market opens on Monday.
NeutralEstrella Immunopharma shares fell about 19% before Monday's open, but the article gives no business reason, so its outlook is unchanged.
12 health care stocks are changing a lot before the market opens on Friday.
NeutralEstrella Immunopharma shares fell 20.2% in the pre-market list. The article gives no company news explaining the move, so it does not change the business outlook.
Estrella Immunopharma, Inc. has been told it might be removed from Nasdaq for not meeting listing rules.
Bad for ESLAEstrella Immunopharma received a Nasdaq delisting notice for low market value; this filing is negative for the company's listing status and outlook.
Estrella Immunopharma, Inc. faces potential delisting after failing to meet ongoing listing standards; listing transfer initiated (ESLAW).
Bad for ESLAEstrella Immunopharma, Inc. has filed a Form 8-K indicating that it has received a notice of delisting due to failure to satisfy continued listing rules. This news is critical as it raises concerns about the company's compliance and future trading status, likely leading to negative investor sentiment and potential sell-offs.